Announces Expanded Multi-Year Software Agreement with Lilly
Continued Focus in 2024 on Advancing Science Underlying Platform, Driving Software Adoption and Progressing Proprietary Pipeline
.
Halia Therapeutics to Present at the 5th Inflammasome Therapeutics Summit streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ EpicentRx, a late clinical stage biopharmaceutical company with novel therapies to target cancer and inflammatory diseases, announced it will.
Family of NLRP3 inhibitors is differentiated by novel structure, central nervous system penetration, and potential for improved safety and efficacyRICHMOND, Calif. (BUSINESS WIRE) #aging BioAge Labs, Inc. (“BioAge”), a privately held clinical-stage biotechnology company developing therapeutics that target the mol.
/PRNewswire/ ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of.